Eli Lilly Began Construction on Houston Diabetes Campus
The 236-acre facility will produce orforglipron, an oral medication approved in 2026 for diabetes management.
Updated on Sept. 21, 2026 in Diabetes
Live Poll
Do you support providing large tax incentives to attract major corporations to your area?
Eli Lilly has officially broken ground on a $6.5 billion manufacturing campus in Houston's Generation Park. The facility will be dedicated to producing orforglipron, a GLP-1 receptor agonist medication that received FDA approval in April 2026.
Why it matters
The new plant aims to increase local supply chain capacity for oral diabetes treatments, which are increasingly sought after by patients seeking alternatives to injectable GLP-1 medications.
The project is a $6.5 billion investment spanning 236 acres, supported by $146 million in state tax incentives and a $5.5 million grant. These figures represent the total capital expenditure and public funding committed to the project versus zero prior infrastructure.
The players
Eli Lilly
A pharmaceutical company focused on cardiometabolic health, diabetes, and oncology treatments.
FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
The details
The site will feature over 808,000 square feet of manufacturing space specifically designed to produce the oral diabetes drug orforglipron. This medication works by mimicking the body's natural incretin hormones to help regulate blood glucose levels in people with type 2 diabetes. By transitioning from injectable to oral formats, Eli Lilly aims to provide a different delivery mechanism for patients managing their condition.
Timeline
April 2026: The FDA approved the medication orforglipron.
September 21, 2026: The official ground-breaking ceremony for the Houston campus took place.
November 2027: Construction is expected to be completed.
Health Landscape
This development marks a significant expansion in the manufacturing infrastructure supporting the current surge in demand for GLP-1 receptor agonist therapies. It reflects a broader trend of domesticating production for essential metabolic disease treatments within the United States.
As new production facilities like this come online, the availability and distribution of oral diabetes medications may eventually see improvements. Patients currently taking or interested in GLP-1 treatments should discuss the changing landscape of options with their physician.
The takeaway
The construction of this facility signals a long-term investment in the production of oral treatments for metabolic conditions. Patients should stay informed about new medication options and speak with their doctor about whether oral GLP-1 therapies are appropriate for their personal care plan.
Further reading
For more information on the current tools available for glucose management, visit our Diabetes section.
Live Poll
Do you support providing large tax incentives to attract major corporations to your area?
